• Skip to primary navigation
  • Skip to main content
  • Skip to footer
NICO CorporationSecondary logo

NICO Corporation

Dedicated to revolutionizing minimally invasive neurosurgery

  • Home
  • Patients
  • Professionals
    • Our Capabilities
    • Our Integrated System
    • Our Surgical Focus
    • Our Impact
    • Published Data
    • Investigator Initiated Study Program
      • IIS Program Overview
      • IIS Areas of Interest (AOIs)
    • Donation Request
    • Global Distribution
    • NICO Technologies for Animal Health
    • Neurosurgeon Education
  • Company
    • Our Mission
    • Our Leadership Team
    • News & Events
    • Careers
  • LinkedIn
  • Twitter
  • YouTube

Cerebral Cavernous Malformations (CCMs)

Home » Our Surgical Focus » Cerebral Cavernous Malformations (CCMs)

What is the incidence of cerebral cavernous malformations in the United States?

1 in 500 people have a CCM1

Majority will have no symptoms2

1 in 500 people have a CCM

CCMs are the most common vascular abnormality,

making up 10 – 25% of all vascular malformations3Cavernous Malformation - CCMs

 


 

What challenges have been encountered with conventional surgical approaches?

  1. Safe access to deeper CM’s particularly in the insula, basal ganglia & thalamus4
  2. Deficits – Morbidity4,5

 


 

How does the MIPS approach with NICO’s integrated systems solution overcome these challenges?

Challenge #1 – Safe access to deeper CM’s

Solution: The MIPS approach using NICO’s systems solution provides non-disruptive subcortical access and may enable complete removal of the offending lesion as highlighted in the following publications:

TABLE 1 - Summary of Patients Treated With Minimally Invasive Parafascicular Approach Utilizing the BrainPath System (NICO Corp) for Resection of Cerebral Cavernous Malformations

PatientAge, sexPresentationLocationComplete resectionComplicationsFollow-up (months)
121, femaleHeadachesRight frontalYesNone41
236, maleSeizureLeft frontalYesWound Dehiscence17
364, femaleIncidentalLeft ParietalYesNone10
426, femaleSeizureRight ParietalYesNone22
519, maleSeizureLeft frontalYesNone5
623, maleSeizureRight TemporalYesNone24
Goren, et al

 


TABLE 2 - Summary of cerebral cavernous malformation patients treated with endoport-assisted microsurgical resection

PatientAge (years), sexClinical presentationmRS at presentationCCM maximum diameter cm/volume (cm3)LocationComplete resectionComplicationsFollow-up (months)mRS score at follow-up
128, femaleSyncope, tongue and arm numbness24.5/41.0Corpus callosumNoNone20
226, femaleHeadache20.7/0.17Left frontalYesNone62
347, femaleHeadache21.0/0.63Corpus callosumYesNone122
Ding, et al

 

Challenge #2 – Deficits – Morbidity
Solution: The MIPS approach using NICO’s systems solution may enable preservation of neurological function as highlighted in the following publications:

  • “Obviated the need for dissection of sylvian & hemispheric fissures”5
  • “Tubular retractor is aided by maintaining full brain and increases accuracy of navigation…Normal to slightly elevated ICP drives lesion, particularly hematoma into sheath, limits dissection off of critical structures”5
  • “The BrainPath system allows for a trans-sulcal approach which splits the white matter fiber tracts rather than cutting through them and thereby minimizes damage to the surrounding brain tissue. With preoperative DTI, the port also allows for trajectory planning avoiding white matter tracts that surround the lesion. This is particularly relevant for CM’s located in eloquent brain. When choosing the surgical trajectory, utilizing the information generated by the navigation sequence and DTI, we do not necessarily consider the shortest path from the surface to the lesion as correct one. By harnessing both technologies, the BrainPath system & DTI, we aim for the safest path that would keep both white matter tracts and gray matter intact, respectively”6
  • “While endoport splitting of white matter fibers is not entirely atraumatic due to mechanical stretching tissue, the device circular nature allows more even distribution force compared to traditional retractor blades”7
BrainPath is designed for trans-sulcal access
BrainPath is designed for navigable, trans-sulcal access with an a-traumatic conical tip that gradually dilates the tissue during cannulation

 

BrainPath sheath
BrainPath sheath acts as a protective portal for displaced neural tissue

 


 

Key Publications

Goren, et al. Minimally Invasive Surgery for Resection of Cerebral Cavernous Malformations Utilizing Image-Guided BrainPath System. Operative Neurosurgery 2018


Ding, et al Endoport-assisted microsurgical resection of cerebral cavernous malformations. J. Cl in Neuroscience (2015)


Amenta, et al. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management. 5 (2016) 12-17

 


 

Citations

  1. Mouchtouris, et al. Management of Cerebral Cavernous Malformations: From Diagnosis to Treatment. Scientific World Journal Volume 2015, ID 808314, 8 pages
  2. Angioma Alliance Website
  3. AANS website
  4. Awad, et al. Cavernous angiomas: deconstructing a neurosurgical disease. J Neurosurgery Volume 131. July 2019
  5. Amenta, et al. Resection of left posterolateral thalamic cavernoma with NICO BrainPath Sheath: Case Report, technical note and review of the literature. Interdisciplinary Neurosurgery: Advance Techniques 5 (2016) 12-17
  6. Goren, et al. Minimally Invasive Parafascicular Surgery for Resection of Cerebral Cavernous Malformations utilizing Image-Guided BrainPath System. Operative Neurosurgery 2018
  7. Ding, et al. Endoport-assisted microsurgical resection of cerebral cavernous malformations. J. Cl in Neuroscience (2015)

Footer

OUR MISSION is SIMPLE

We provide proven and patented technologies that integrate imaging and intervention for a safe, minimally disruptive approach to brain surgery. This integration drives efficiencies for the patient, surgeon and healthcare provider.

Customer Service

 Tel: (317) 660-7118
 Email Us

Follow NICO Here

  • LinkedIn
  • Twitter
  • YouTube
Social Media Links

Search Our Website

privacy policy   ·    terms of use   ·    patents    ·   labeling

Copyright © 2023 · Nico Corporation · NICO Myriad and BrainPath are “tools” not “treatments”. Physicians should use their best judgment and clinical experience when deciding how to use the Myriad and BrainPath. The latest information, including contraindications, warnings and precautions can be obtained by consulting product labeling or your local NICO representative.